Metformin for prevention of type 2 diabetes.
نویسندگان
چکیده
OBJECTIVE To evaluate evidence from the medical literature that metformin is effective in preventing type 2 diabetes. DATA SOURCES Primary literature was accessed via a MEDLINE search (1966-December 2003) using the terms metformin, type 2 diabetes, and prevention. DATA SYNTHESIS Two studies evaluated metformin's potential to prevent type 2 diabetes, finding that metformin maintained or reduced fasting blood glucose in non-diabetics. Recently, a large study by the Diabetes Prevention Program showed that metformin may reduce the incidence of diabetes. Researchers compared lifestyle changes, metformin therapy, and placebo groups. They found that both lifestyle changes (58%) and metformin therapy (31%) significantly reduced the occurrence of type 2 diabetes versus placebo. CONCLUSIONS These studies provide evidence that metformin may reduce the occurrence of type 2 diabetes. Because long-term efficacy has not been determined, further studies are needed.
منابع مشابه
Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.
This review describes the effect of lifestyle change or metformin compared with standard care on incident type 2 diabetes and cardiometabolic risk factors in the Diabetes Prevention Program and its Outcome Study. The Diabetes Prevention Program was a randomized controlled clinical trial of intensive lifestyle and metformin treatments versus standard care in 3234 subjects at high risk for type 2...
متن کاملThe C Allele of ATM rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program
OBJECTIVE The C allele at the rs11212617 polymorphism in the ataxia-telangiectasia-mutated (ATM) gene has been associated with greater clinical response to metformin in people with type 2 diabetes. We tested whether this variant modified the effect of metformin in the Diabetes Prevention Program (DPP), in which metformin reduced diabetes incidence by 31% in volunteers with impaired glucose tole...
متن کاملPharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients
Type 2 diabetes mellitus is a worldwide epidemic disorder with considerable health and economic consequences. Metformin is one of the most commonly prescribed oral antidiabetic drugs. Pharmacogenetic studies showed that variants in genes related to the pharmacokinetics of metformin were associated with glucose-lowering effect of metformin. The aim of this study was to evaluate pharmacogenetic v...
متن کاملPreventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?
The secondary analysis of the Diabetes Prevention Program (DPP) showed that withdrawal of metformin for 1-2 weeks resulted in a trend to a higher conversion rate from impaired glucose tolerance to diabetes as compared with the placebo group (1). This resulted in a reduction by 26% of the so-called prevention effect of metformin, i.e., from 31% in the primary analysis (2) to 25% in the secondary...
متن کاملMetformin may improve the prognosis of patients with pancreatic cancer.
BACKGROUND Pancreatic cancer risk is increased in patients with type 2 diabetes, while being reduced by metformin treatment. However, it is unclear whether metformin could be associated with clinical outcomes of patients with pancreatic cancer and concurrent type 2 diabetes. MATERIALS AND METHODS A pooled analysis of 4 publications including 1,429 patients was performed to investigate the ass...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Annals of pharmacotherapy
دوره 38 7-8 شماره
صفحات -
تاریخ انتشار 2004